BNTC — Benitec Biopharma Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1808898 ·
Last close
$8.15
Market Cap
$284.35M
52W High
$14.39
52W Low
$7.89
ADV30
185,285
Next earnings
2027-02-11
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -14,477,000 -12,925,000 179,098,000 176,368,000 9,451,000
Jun 2026 0 — -14,430,000 -12,809,000 182,623,000 179,972,000 5,610,000
Mar 2026 0 — -13,582,000 -11,935,000 187,000,000 184,761,000 3,668,000
Dec 2025 0 — -13,377,000 -11,837,000 190,681,000 188,790,000 3,320,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-16,518,000
Investing CF
$-100,000
Financing CF
$98,977,000
CapEx
$-100,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.10
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-273,722,000
Inventory
—
Receivables
$4,000
ST Investments
—
EBIT TTM
$-51,192,000
Pretax Income TTM
$-45,546,000
Interest Exp TTM
—
Analysts
7

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Jun 2026 0 -51,192,000 -45,546,000 182,623,000 5,610,000 177,013,000 -16,518,000
Jun 2025 0 -41,765,000 -37,917,000 99,592,000 2,297,000 97,295,000 -23,588,000
Jun 2024 0 -22,490,000 -21,751,000 52,210,000 4,962,000 47,248,000 -19,403,000
Jun 2023 75,000 -19,081,000 -19,562,000 4,464,000 4,262,000 202,000 -18,012,000
Jun 2022 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-45,546,000
OpCashFlow TTM
—
Assets (Latest)
$187,000,000
Forward EPS
$-9.42

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $10.00 · spot: $8.27 · call volume: 2 · put volume: 1
Expected Move to 2027-01-15: ±$7.50 (90.69%) — implied range $0.77 – $15.77 · ATM straddle on $10.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
VCRE Vicore Pharma Holding AB $285.02M $10.12 —
FULC Fulcrum Therapeutics, Inc. $286.43M $3.75 —
MPLT MapLight Therapeutics, Inc. $286.78M $6.57 —
EBS Emergent BioSolutions Inc. $288.44M $5.61 —
EVMN Evommune, Inc. $290.28M $7.02 —

News headlines (Yahoo Finance, 1h cache)

UPDATED -- Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update
2026-11-13 14:12 · Yahoo
Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update
2026-11-13 13:00 · Yahoo
RNA Interference (RNAi) - Global Strategic Business Report: Capture the US$8 Billion 2032 Market as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Qiagen, Benitec BioPharma, and Silence Therapeutics
2026-11-12 14:06 · Yahoo
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301
2026-10-28 12:00 · Yahoo
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
2026-10-05 12:00 · Yahoo
After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)
2026-09-25 12:35 · Yahoo
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
2026-05-14 12:00 · Yahoo
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of
2026-04-28 11:00 · Yahoo
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
2026-09-14 20:00 · Yahoo
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, th
2026-03-10 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.